BioSpace News Archive

The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”

Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.

Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.

Cyteir Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination with three standard-of-care chemotherapy regimens in both hematologic malignancies and solid tumors.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), today announced key research data published in two leading peer-reviewed industry journals highlighting the durability and cost-effectiveness of its proprietary Deep TMS™ treatment for patients coping with obsessive-compulsive disorder (OCD).

Conference call to be held on February 10 at 8:30 a.m. Eastern Time to release its financial results for the fourth quarter and full year 2021 before the Nasdaq market opens on Thursday, February 10, 2022.

It is with profound sadness that Hepion Pharmaceuticals, Inc. announces the passing of Thomas Adams, Ph.D., a member of its Board of Directors.

electroCore, Inc. today announced that its gammaCore™ nVNS device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the treatment of posttraumatic stress disorder (PTSD) after showing a reduction of symptoms of PTSD by 31% when compared to sham.

Xenon Pharmaceuticals Inc. today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon.

Immix Biopharma, Inc. today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer.